Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Scrip's Five Must-Know Things: new developments in the TIGIT field; doctor frustration over Aduhelm guidance; are pediatric COVID vaccines necessary: the battle of the SERDs; and one Indian firm’s plans for lung disease leadership.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 18 June 2021, including: new developments in the TIGIT field; doctor frustration over Aduhelm guidance; are pediatric COVID vaccines necessary: the battle of the SERDs; and one Indian firm’s plans for lung leadership.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "GSK Spends Heavily On iTeos' TIGIT To Build A New IO Cornerstone" - Scrip, 14 Jun, 2021.)
(Also see "Doctors Frustrated By Lack Of Guidance On Who Should Get Aduhelm" - Scrip, 12 Jun, 2021.)
(Also see "Does New Study Question Need for Pediatric COVID-19 Vaccines?" - Scrip, 14 Jun, 2021.)
(Also see "ASCO Data Position Contenders In Battle Of The SERDs" - Scrip, 14 Jun, 2021.)
(Also see "How Cipla Is Shaping Lung Leadership Beyond Asthma, AMR Plans" - Scrip, 14 Jun, 2021.)